192945-57-6

Basic information

• Product Name: Methyl 3-bromo-1-methylindazole-6-carboxylate
• Synonyms: Methyl 3-bromo-1-methylindazole-6-carboxylate;Methyl 3-broMo-1-Methylin...;methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate
• CAS NO: 192945-57-6
• Molecular Formula: C10H9BrN2O2
• Molecular Weight: 269.09466
• Mol File: 192945-57-6.mol

Chemical Properties

• Boiling Point: 366.7°C at 760 mmHg
• Flash Point: 175.6°C
• Appearance: /
• Density: 1.61g/cm³
• Vapor Pressure: 1.44E-05mmHg at 25°C
• Refractive Index: 1.638
• CAS DataBase Reference: Methyl 3-bromo-1-methylindazole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-bromo-1-methylindazole-6-carboxylate(192945-57-6)
• EPA Substance Registry System: Methyl 3-bromo-1-methylindazole-6-carboxylate(192945-57-6)

Safety Data

• Hazardous Substances Data: 192945-57-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-bromo-1-methylindazole-6-carboxylate is used as an intermediate in the synthesis of pharmaceuticals for its potential applications in the development of new drugs. Its unique structural and chemical properties allow it to be a key component in the creation of various medicinal compounds.
Used in Organic Compounds Synthesis:
Methyl 3-bromo-1-methylindazole-6-carboxylate is used as an intermediate in the synthesis of organic compounds due to its reactive functional groups and compatibility with various chemical reactions. This allows for the development of a wide range of chemical products with diverse applications.
Used in Chemical Research:
Methyl 3-bromo-1-methylindazole-6-carboxylate is utilized in chemical research as a model compound to study the properties and reactions of indazoles and their derivatives. This helps in understanding the reactivity, stability, and potential applications of similar compounds in various fields.

InChI:InChI=1/C10H9BrN2O2/c1-13-8-5-6(10(14)15-2)3-4-7(8)9(11)12-13/h3-5H,1-2H3

Upstream product

• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 192945-56-5 methyl 3-bromo-1H-indazole-6-carboxylate 
• 74-88-4 methyl iodide 

Relevant articles and documents

Sodium channel blockers (by machine translation)

The invention belongs to the field of medicines, and particularly relates to a compound shown as a formula (I). A pharmaceutical composition comprising the compound, a pharmaceutically acceptable salt, a solvate or an isomer thereof, a pharmaceutically ac

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain

3-Aryl-indole and 3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund's adjuvant (CFA)-induced thermal hyper

ACYL SULFONAMIDE NaV1.7 INHIBITORS

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.